Valuation : Insmed Incorporated

Market Cap 27.65B 23.86B 22.47B 20.48B 38.27B 2,612B 38.56B 266B 103B 1,336B 104B 102B 4,387B P/E 2026 *
-77.5x
P/E 2027 * 141x
Enterprise Value 27.02B 23.31B 21.96B 20.01B 37.4B 2,553B 37.68B 260B 101B 1,305B 101B 99.25B 4,287B EV / Sales 2026 *
15x
EV / Sales 2027 * 9.18x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week+3.72%
Current month+3.35%
1 month+27.88%
3 months+21.22%
6 months-14.35%
Current year-27.66%
1 week 117.15
Extreme 117.15
126.87
1 month 97.86
Extreme 97.86
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
8/6/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%+3.72%-12.26%+377.44% 27.65B
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.29%+0.42%+49.28%+91.87% 65.29B
+2.97%+0.40%+38.60%+12.79% 25.77B
-1.12%-7.92%+2.15%-15.92% 26.08B
+1.43%+1.62%+26.77%-17.31% 20.14B
-0.38%-17.67%+214.37%+373.18% 17.03B
+0.77%-5.28%-3.25%+539.79% 15.03B
+0.89%+6.77%+59.63%+164.93% 14.5B
-0.09%+0.55%+25.60%+196.31% 12.64B
Average +0.55%-2.62%+44.02%+181.77% 29.3B
Weighted average by Cap. +0.72%-2.18%+40.83%+142.85%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.47B 1.34B 2.5B 171B 2.52B 17.38B 6.75B 87.24B 6.78B 6.63B 287B 2.89B 2.49B 2.35B 2.14B 3.99B 273B 4.02B 27.77B 10.78B 139B 10.84B 10.6B 458B
Net income -349M -301M -284M -259M -484M -33B -487M -3.36B -1.3B -16.87B -1.31B -1.28B -55.43B 211M 182M 172M 157M 293M 19.97B 295M 2.03B 789M 10.21B 794M 777M 33.54B
Net Debt -632M -545M -513M -468M -874M -59.68B -881M -6.08B -2.36B -30.51B -2.37B -2.32B -100B -1.16B -998M -940M -856M -1.6B -109B -1.61B -11.13B -4.32B -55.86B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-09-03 US$125.62 -0.80% 383,467
26-09-02 US$126.63 +4.21% 1,998,834
26-09-01 US$121.51 -0.25% 1,419,286
26-08-31 US$121.82 +2.77% 2,390,325
26-08-28 US$118.54 -2.35% 1,977,867
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
126.63USD
Average target price
200.18USD
Spread / Average Target
+58.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock